维普中文期刊产品整合服务
1篇 您的检索式:作者名="Benjamin S.Simpson"
    题名 作者 年代 出处 被引量
1PIM kinase inhibition:co-targeted therapeutic approaches in prostate cancer显示文摘PIM kinases have been shown to play a role in prostate cancer development and progression,as well as in some of the hallmarks of cancer,especially proliferation and apoptosis.Their upregulation in prostate cancer has been correlated with decreased patient overall survival and therapy resistance.Initial efforts to inhibit PIM with monotherapies have been hampered by compensatory upregulation of other pathways and drug toxicity,and as such,it has been suggested that co-targeting PIM with other treatment approaches may permit lower doses and be a more viable option in the clinic.Here,we present the rationale and basis for cotargeting PIM with inhibitors of PI3K/mTOR/AKT,JAK/STAT,MYC,stemness,and RNA Polymerase I transcription,along with other therapies,including androgen deprivation,radiotherapy,chemotherapy,and immunotherapy.Such combined approaches could potentially be used as neoadjuvant therapies,limiting the development of resistance to treatments or sensitizing cells to other therapeutics.To determine which drugs should be combined with PIM inhibitors for each patient,it will be key to develop companion diagnostics that predict response to each co-targeted option,hopefully providing a personalized medicine pathway for subsets of prostate cancer patients in the future.Sabina Luszczak Christopher Kumar Vignesh Krishna Sathyadevan Benjamin S.Simpson Kathy A.Gately Hayley C.Whitaker Susan Heavey 2020Signal Transduction and Targeted Therapy2020,5,1:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费